A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL)

Active:	No
Cancer Type:	Hematopoietic Malignancies Lymphoma Non-Hodgkin Lymphoma Unknown Primary	NCT ID:	NCT05879744
Trial Phases:	Phase I	Protocol IDs:	CLN-978-001 (primary) NCI-2023-04426
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Cullinan Therapeutics Inc.
NCI Full Details:	http://clinicaltrials.gov/show/NCT05879744

Summary

CLN-978-001 is a Phase 1, open-label, dose escalation and dose expansion study of CLN-978
in patients with Relapse/Refractory (R/R) B-cell Non-Hodgkin Lymphoma (B-NHL).

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
404-778-5180
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.